Core Viewpoint - Eli Lilly (LLY) is positioned to potentially continue its earnings-beat streak in the upcoming report, having a history of exceeding earnings estimates, particularly in the last two quarters with an average surprise of 14.54% [1] Earnings Performance - For the last reported quarter, Eli Lilly achieved earnings of $7.02 per share, surpassing the Zacks Consensus Estimate of $6.02 per share, resulting in a surprise of 16.61% [2] - In the previous quarter, the company was expected to report earnings of $5.61 per share but delivered $6.31 per share, yielding a surprise of 12.48% [2] Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Eli Lilly, with a positive Zacks Earnings ESP (Expected Surprise Prediction), indicating a strong likelihood of an earnings beat [5] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have historically produced a positive surprise nearly 70% of the time, suggesting a high probability of exceeding consensus estimates [6] Earnings ESP Metric - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which may be more accurate [7] - Eli Lilly currently has an Earnings ESP of +0.05%, indicating recent bullish sentiment among analysts regarding the company's earnings prospects [8] Upcoming Earnings Report - The next earnings report for Eli Lilly is expected to be released on February 4, 2026, and the combination of a positive Earnings ESP and a Zacks Rank of 3 suggests a potential for another earnings beat [8]

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Exponent (EXPO) , which belongs to the Zacks Consulting Services industry.This engineering and scientific consulting company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 9.17%.For the most recent quarter, Exponent was expected to post earnings of $ ...

Core Viewpoint - WEC Energy Group is positioned well to continue its trend of beating earnings estimates in upcoming quarterly reports [1] Earnings Performance - WEC Energy has a strong history of exceeding earnings estimates, with an average surprise of 6.05% over the last two quarters [2] - In the most recent quarter, the company reported earnings of $0.83 per share, surpassing the expected $0.79 per share by 5.06% [2] - For the previous quarter, WEC Energy's actual earnings were $0.76 per share against an estimate of $0.71 per share, resulting in a surprise of 7.04% [2] Earnings Estimates and Predictions - Recent earnings estimates for WEC Energy have been revised upward, indicating positive sentiment among analysts [5] - The Zacks Earnings ESP for WEC Energy is currently +0.58%, suggesting bullish expectations for near-term earnings [8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) indicates a strong possibility of another earnings beat [8] Statistical Insights - Stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [6] - The Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [7]

Core Insights - Amgen (AMGN) is set to report its fourth-quarter and full-year 2025 results on February 3, with earnings expected to be $4.74 per share and sales at $9.46 billion, reflecting a 12.8% earnings surprise in the last reported quarter [1][10]. Group 1: Sales Performance - Product sales are anticipated to be driven by strong volume growth from drugs like Evenity, Repatha, and Blincyto, although prices are expected to decline due to increased rebates [2]. - The Zacks Consensus Estimate for sales of Evenity, Repatha, and Blincyto is $559 million, $798 million, and $434 million, respectively [3]. - Newer drugs such as Imdelltra, Tavneos, and Tezspire are expected to contribute to top-line growth, alongside sales from rare disease drugs like Uplizna, estimated at $183 million [4]. Group 2: Patent Expirations and Competitive Pressures - Patents for key drugs Prolia and Xgeva expired in February 2025 in the U.S., leading to expected sales erosion due to the launch of biosimilars, with estimates of $980 million for Prolia and $444 million for Xgeva [5]. - Competitive pressures have negatively impacted volume growth for Kyprolis, with an estimated sales figure of $365 million, while Enbrel sales are likely to decline due to price reductions [6]. Group 3: Biosimilars and R&D Costs - Amgen's biosimilars, including Wezlana and Pavblu, are expected to contribute to sales growth, although Wezlana is not expected to generate U.S. sales in the fourth quarter [7]. - Lower revenues from oncology biosimilars and legacy products are anticipated, alongside higher R&D costs that may negatively impact operating margins [8][9]. Group 4: Earnings Expectations - Amgen's Earnings ESP is -0.40%, indicating a lower likelihood of an earnings beat, with the most accurate estimate at $4.72 per share compared to the consensus of $4.74 [13][14].

Core Viewpoint - A. O. Smith Corporation (AOS) is set to release its fourth-quarter 2025 results on January 29, with expectations of a slight revenue increase but a decline in adjusted earnings per share [1][2][10]. Financial Performance Expectations - The Zacks Consensus Estimate for AOS's revenues is $923.7 million, reflecting a 1.2% increase from the prior-year quarter [2]. - The consensus estimate for adjusted earnings is 84 cents per share, indicating a 1.2% decline from the year-ago quarter [2]. Segment Performance Insights - Strong demand for commercial water heaters and boilers is anticipated to boost the North America segment's revenues by 1.8% year over year to $702.4 million [3]. - Recent acquisitions, including the Pureit business from Unilever and Impact Water Products, are expected to positively impact AOS's top line and enhance its water treatment offerings [4][5]. Challenges and Risks - The ongoing challenges in the Chinese real estate market are likely to negatively affect the Rest of the World segment, with expected revenues decreasing by 3% year over year to $229.6 million [6]. - AOS is facing rising costs, with SG&A expenses projected to increase by 11.1% year over year to $202.2 million, which may pressure its bottom line [7]. - Foreign currency headwinds are also expected to impact profitability due to the company's significant international operations [7]. Earnings Prediction Insights - The current Earnings ESP for AOS is 0.00%, indicating no expected earnings beat, as both the Most Accurate Estimate and the Zacks Consensus Estimate are at 84 cents per share [9]. - AOS holds a Zacks Rank of 3, suggesting a neutral outlook for the stock [11].

Core Insights - Snap (SNAP) is set to report its fourth-quarter 2025 results on February 4, with expected revenues of $1.7 billion, reflecting a 9.12% increase year-over-year, while earnings per share are estimated at 15 cents, indicating a 6.25% decline from the previous year [1][7]. Group 1: Financial Expectations - The Zacks Consensus Estimate for Snap's fourth-quarter revenues is currently pegged at $1.7 billion, indicating a 9.12% increase from the year-ago quarter's reported figure [1]. - The consensus mark for earnings is pegged at 15 cents per share, which has remained unchanged over the past 30 days, implying a 6.25% decline from the year-ago quarter's earnings of 16 cents [1]. Group 2: Recent Performance and Trends - Snap has surpassed the Zacks Consensus Estimate for earnings in three of the trailing four quarters, while missing it once, with an average negative surprise of 46.43% [2]. - The company is expected to have entered the fourth quarter of 2025 with improving advertising momentum, particularly in the Small and Medium-sized Business (SMB) segment, which is anticipated to show robust growth rates [3]. - The advertising platform's machine learning investments are expected to have driven improved attribution accuracy, particularly for purchase-related advertising, which is projected to grow substantially faster than overall ad revenue [3]. Group 3: Content Engagement and Innovations - Content engagement trends are expected to have strengthened due to improvements in the company's recommendation model, with significant year-over-year increases in Spotlight views [4]. - The creator ecosystem is anticipated to have expanded rapidly, with Snap Star activity growing nearly 180% year-over-year in North America [4]. - New product launches, such as Animate It and Quick Cut, along with expansion to Amazon Fire Tablets, are expected to enhance user engagement and accessibility [4]. Group 4: Challenges and Headwinds - Fourth-quarter results are expected to reflect significant headwinds from regulatory pressures, including Australia's social media minimum age law, which is likely to have caused immediate user attrition [5]. - The rollout of platform-level age verification is expected to pressure daily active user metrics across multiple geographies [5]. - The introduction of Memory Storage Plans, which end unlimited free storage for users exceeding 5GB, is likely to have generated resistance among engaged users [5].

Core Insights - Aon plc is scheduled to report its fourth-quarter 2025 results on January 30, 2026, with earnings estimated at $4.76 per share and revenues at $4.38 billion [1][5] Financial Performance - The fourth-quarter earnings estimate reflects a year-over-year increase of 7.7%, while the revenue estimate indicates a growth of 5.5% compared to the previous year [2] - For the full year 2025, Aon's revenue is projected at $17.26 billion, representing a 9.9% year-over-year increase, and earnings per share are expected to be $16.96, indicating an 8.7% growth [3] Earnings History - Aon has beaten the consensus estimate in three of the last four quarters, with an average surprise of 1.6% [3] - The reported earnings for the last four quarters were as follows: $3.05, $3.49, $5.67, and $4.42, with an average surprise of 1.58% [4] Revenue Growth by Segment - The Commercial Risk Solutions segment is expected to see a revenue growth of 6.2% year-over-year, while the Health Solutions segment is projected to grow by 7.1% [9][10] - The Reinsurance Solutions segment is estimated to grow by 5.8%, benefiting from favorable retention rates and new business generation [11] - The Wealth Solutions segment, however, is expected to decline by 0.9% due to divestments [12] Operating Expenses - Total operating expenses for the fourth quarter are projected to exceed $3.1 billion, primarily driven by increased compensation and benefits expenses [12]

Core Viewpoint - Exxon Mobil Corporation (XOM) is expected to report its fourth-quarter 2025 results on January 30, with earnings per share (EPS) estimated to rise by 0.6% year-over-year, while revenues are projected to decline by 0.3% compared to the previous year [1][2][6]. Earnings Estimates - The Zacks Consensus Estimate for fourth-quarter earnings is $1.68 per share, reflecting a slight improvement from the previous year [2]. - The estimated revenue for the fourth quarter is $83.2 billion, indicating a decrease from the year-ago figures [2]. - XOM has consistently beaten earnings estimates in the past four quarters, with an average surprise of 5.7% [2]. Earnings Prediction Model - The current model does not predict an earnings beat for XOM, as it has an Earnings ESP of -0.25% and a Zacks Rank of 3 (Hold) [3]. Factors Impacting Earnings - XOM anticipates a sequential decline in upstream earnings by $800 million to $1.2 billion due to lower liquid prices [5]. - The average WTI spot prices for the last quarter were significantly lower than the previous quarter, which may have negatively impacted upstream operations [7]. - Natural gas prices could either increase upstream earnings by $100 million or decrease them by $300 million [8]. Price Performance and Valuation - XOM's stock has increased by 25.9% over the past year, outperforming BP and Chevron [9]. - The current EV/EBITDA ratio for XOM is 8.84, which is above the industry average of 5.43, indicating a premium valuation [11]. Long-term Outlook - Despite the challenges posed by lower crude prices, XOM's long-term outlook remains positive due to its strong presence in the Permian Basin and offshore Guyana, where it has made significant discoveries [14][15]. - The company employs advanced technologies to enhance well recoveries, which could mitigate some impacts of low crude prices [14]. Status of Competitors - Chevron (CVX) and BP are also set to report their fourth-quarter earnings soon, with CVX having a negative Earnings ESP and BP showing a positive outlook [16][17].

Core Viewpoint - AbbVie (ABBV) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended December 2025, with earnings expected to be $3.02 per share, reflecting a +39.8% change, and revenues projected at $16.38 billion, up 8.5% from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for February 4, and the stock may rise if the reported figures exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 0.32% higher in the last 30 days, indicating a slight positive adjustment from analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that AbbVie has a negative Earnings ESP of -12.44%, suggesting analysts have become bearish on the company's earnings prospects [12]. - Despite the negative Earnings ESP, AbbVie holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12]. Historical Performance - AbbVie has a history of beating consensus EPS estimates, having done so in the last four quarters, with a recent surprise of +5.08% when it reported earnings of $1.86 per share against an expectation of $1.77 [13][14]. Industry Context - In the broader pharmaceutical industry, Merck (MRK) is also expected to report earnings of $2.04 per share for the same quarter, reflecting a year-over-year change of +18.6%, with revenues projected at $16.19 billion, up 3.6% [18]. - Merck's consensus EPS estimate has been revised down by 85.2% over the last 30 days, and it currently has an Earnings ESP of +0.33% but holds a Zacks Rank of 4, complicating predictions for an earnings beat [19][20].

Wex (WEX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 4. On th ...